RS20060113A - Stable polymorph of bifeprunox mesylate (7-(4-(1,1'- biphenyl)-3-ylmetheyl0-1-piperazinyl)-2(3h)-benzoxazolone monomethanesulfonate - Google Patents

Stable polymorph of bifeprunox mesylate (7-(4-(1,1'- biphenyl)-3-ylmetheyl0-1-piperazinyl)-2(3h)-benzoxazolone monomethanesulfonate

Info

Publication number
RS20060113A
RS20060113A YUP-2006/0113A YUP20060113A RS20060113A RS 20060113 A RS20060113 A RS 20060113A YU P20060113 A YUP20060113 A YU P20060113A RS 20060113 A RS20060113 A RS 20060113A
Authority
RS
Serbia
Prior art keywords
piperazinyl
biphenyl
ylmetheyl0
stable polymorph
bifeprunox mesylate
Prior art date
Application number
YUP-2006/0113A
Other languages
English (en)
Inventor
Klaas Zwier
Gerrit Klein
Irene Eijgendaal
Amstel Maria Ter Horst-Van
Original Assignee
Solvay Pharmaceuticals B.V.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20060113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharmaceuticals B.V., filed Critical Solvay Pharmaceuticals B.V.,
Publication of RS20060113A publication Critical patent/RS20060113A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pronalazak se odnosi na stabilni polimorfni oblik jedinjenja 7-[4-([1,1'-bifenil]-3-ilmetil)-1-piperazinil]-2(3H)-benzoksazolon monometansulfonata (INNM bifeprunoks mezilat), postupak za pripremanje navedenog polimorfnog oblika i njegovu upotrebu u farmaceutskim proizvodima, posebno u farmaceutskim proizvodima za lečenje psihotičnih poremećaja i Parkinsonove bolesti.
YUP-2006/0113A 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesylate (7-(4-(1,1'- biphenyl)-3-ylmetheyl0-1-piperazinyl)-2(3h)-benzoxazolone monomethanesulfonate RS20060113A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49570803P 2003-08-18 2003-08-18
EP03102573 2003-08-18
PCT/EP2004/051816 WO2005016898A2 (en) 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesilate

Publications (1)

Publication Number Publication Date
RS20060113A true RS20060113A (en) 2008-09-29

Family

ID=34924088

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2006/0113A RS20060113A (en) 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesylate (7-(4-(1,1'- biphenyl)-3-ylmetheyl0-1-piperazinyl)-2(3h)-benzoxazolone monomethanesulfonate

Country Status (26)

Country Link
EP (1) EP1656358B1 (sr)
JP (1) JP2007502802A (sr)
CN (1) CN100422159C (sr)
AR (1) AR045362A1 (sr)
AT (1) ATE499348T1 (sr)
AU (1) AU2004265104B2 (sr)
BR (1) BRPI0413617A (sr)
CA (1) CA2536149C (sr)
DE (1) DE602004031534D1 (sr)
DK (1) DK1656358T3 (sr)
EA (1) EA008182B1 (sr)
ES (1) ES2361508T3 (sr)
IS (1) IS8279A (sr)
ME (1) MEP37108A (sr)
MX (1) MXPA06001881A (sr)
MY (1) MY139462A (sr)
NO (1) NO20061265L (sr)
NZ (1) NZ545415A (sr)
PL (1) PL1656358T3 (sr)
PT (1) PT1656358E (sr)
RS (1) RS20060113A (sr)
SI (1) SI1656358T1 (sr)
TW (1) TWI336695B (sr)
UA (1) UA85562C2 (sr)
WO (1) WO2005016898A2 (sr)
ZA (1) ZA200601399B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
WO2007144422A2 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
KR20090063228A (ko) * 2006-08-31 2009-06-17 솔베이 파마슈티칼스 비. 브이 정신분열증 치료용 비페프루녹스를 위한 적정 계획 및 이에사용하기 위한 키트
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9675101B2 (en) 2013-03-15 2017-06-13 Whirlpool Corporation High performance adjustable juicer with whole foods feed chute
US9556916B2 (en) 2013-03-15 2017-01-31 Whirlpool Corporation High performance adjustable juicer with whole foods feed chute and clutch mechanism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189256B1 (pl) * 1996-03-29 2005-07-29 Duphar Int Res Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO1999032115A1 (en) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos

Also Published As

Publication number Publication date
ES2361508T3 (es) 2011-06-17
PL1656358T3 (pl) 2011-07-29
ATE499348T1 (de) 2011-03-15
NZ545415A (en) 2009-11-27
AR045362A1 (es) 2005-10-26
ZA200601399B (en) 2007-04-25
MEP37108A (en) 2011-02-10
AU2004265104B2 (en) 2009-06-04
UA85562C2 (en) 2009-02-10
WO2005016898A3 (en) 2005-04-07
EP1656358B1 (en) 2011-02-23
CN1835935A (zh) 2006-09-20
EA200600442A1 (ru) 2006-08-25
DK1656358T3 (da) 2011-05-30
NO20061265L (no) 2006-05-09
CA2536149A1 (en) 2005-02-24
EP1656358A2 (en) 2006-05-17
IS8279A (is) 2006-01-31
WO2005016898A2 (en) 2005-02-24
BRPI0413617A (pt) 2006-10-17
TWI336695B (en) 2011-02-01
PT1656358E (pt) 2011-05-12
DE602004031534D1 (de) 2011-04-07
TW200513462A (en) 2005-04-16
MXPA06001881A (es) 2006-05-17
WO2005016898B1 (en) 2005-05-19
AU2004265104A1 (en) 2005-02-24
JP2007502802A (ja) 2007-02-15
EA008182B1 (ru) 2007-04-27
MY139462A (en) 2009-10-30
CN100422159C (zh) 2008-10-01
CA2536149C (en) 2011-03-22
SI1656358T1 (sl) 2011-06-30

Similar Documents

Publication Publication Date Title
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1797878A3 (en) Benzothiazole derivatives
EA017278B9 (ru) Соединения азаиндазола и способы применения
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MXPA06001838A (es) Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
NO20061265L (no) Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
AU2003232805A1 (en) Pharmaceutical active substance combination and the use thereof
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
WO2007030589A3 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
AR037711A1 (es) Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
UY28470A1 (es) Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-(4-(1,1¨-bifenil)-3-ilmetil)-1-piperazinil)-2-(3h)-benzoxazolona)
AU2003277298A8 (en) Pharmaceutical compositions for treatment of parkinson's disease
IL173294A (en) A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it